Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Andrew Scourfield, Catherine Flick, Jack Ross, David M. Wood, Natalie Thurtle, Darryl Stellmach & Paul I. Dargan. (2019) Synthetic cannabinoid availability on darknet drug markets—changes during 2016–2017. Toxicology Communications 3:1, pages 7-15.
Read now
Read now
Vendula Belackova, Martin Pazitny, Eva Drapalova, Magali Martinez, Daan van der Gouwe, Emma Begley, Michal Kidawa, Alexandra Tomkova & Daniela Kmetonynova. (2018) Assessing the impact of laws controlling the online availability of 25I-NBOMe, AH-7921, MDPV and MXE – outcomes of a semi-automated e-shop monitoring. Drugs: Education, Prevention and Policy 25:2, pages 109-117.
Read now
Read now
Sindhu Siddiqi, Charlotte Verney, Paul Dargan & David M. Wood. (2015) Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clinical Toxicology 53:1, pages 54-59.
Read now
Read now
A.-E. Vermette-Marcotte, P. I. Dargan, J. R. H. Archer, S. Gosselin & D. M. Wood. (2014) An Internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine. Clinical Toxicology 52:7, pages 678-681.
Read now
Read now
Articles from other publishers (6)
Bruno Guarita, Vendula Belackova, Daan van der Gouwe, Matthijs Blankers, Martin Pazitny & Paul Griffiths. (2021) Monitoring drug trends in the digital environment–New methods, challenges and the opportunities provided by automated approaches. International Journal of Drug Policy 94, pages 103210.
Crossref
Crossref
Giulia Costa, MariaAntonietta De Luca, Gessica Piras, Jacopo Marongiu, Liana Fattore & Nicola Simola. (2020) Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies. Neural Regeneration Research 15:5, pages 802.
Crossref
Crossref
Rachelle Abouchedid, Thea Gilks, Paul I Dargan, John R. H Archer & David M Wood. (2018) Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances—Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam—in the UK. Journal of Medical Toxicology 14:2, pages 134-143.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
Ananya Mahapatra & Pawan Sharma. (2016) Internet snapshot survey: A novel methodology to monitor novel psychotropic substances and its need in Asia. Asian Journal of Psychiatry 21, pages 7-8.
Crossref
Crossref
Hisham Nizar, Paul I. Dargan & David M. Wood. (2014) Using Internet Snapshot Surveys to Enhance Our Understanding of the Availability of the Novel Psychoactive Substance 4-Methylaminorex and 4,4′-Dimethylaminorex. Journal of Medical Toxicology 11:1, pages 80-84.
Crossref
Crossref